Cargando…

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

BACKGROUND: Immune checkpoint inhibitors (ICI) produce durable antitumor responses but provoke autoimmune toxicities, including uncommon but potentially devastating neurologic toxicities. The clinical features, including the spectrum, timing, and outcomes, of ICI-induced neurologic toxicities are no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Douglas B., Manouchehri, Ali, Haugh, Alexandra M., Quach, Henry T., Balko, Justin M., Lebrun-Vignes, Benedicte, Mammen, Andrew, Moslehi, Javid J., Salem, Joe-Elie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530194/ https://www.ncbi.nlm.nih.gov/pubmed/31118078 http://dx.doi.org/10.1186/s40425-019-0617-x

Ejemplares similares

Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
por: Nguyen, Lee S., et al.
Publicado: (2021)

Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study
por: Hilmi, Marc, et al.
Publicado: (2020)

Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
por: Wright, Jordan J., et al.
Publicado: (2018)

Drug-associated hyperammonaemia: a Bayesian analysis of the WHO Pharmacovigilance Database
por: Balcerac, Alexander, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions
por: Moslehi, Javid, et al.
Publicado: (2022)

Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database
por: Nguyen, Lee S., et al.
Publicado: (2022)

Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database
por: Nguyen, Lee S., et al.
Publicado: (2020)

Sipuleucel‐T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database
por: Moey, Melissa Y.Y., et al.
Publicado: (2021)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Circulating immune checkpoints predict heart failure outcomes
por: Screever, Elles M., et al.
Publicado: (2023)

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
por: Johnson, Douglas B., et al.
Publicado: (2019)

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept
por: Nguyen, Lee S, et al.
Publicado: (2022)

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
por: Hoisnard, Léa, et al.
Publicado: (2022)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Boughdad, Sarah, et al.
Publicado: (2021)

Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19
por: Binois, Yannick, et al.
Publicado: (2020)

Smoldering myocarditis following immune checkpoint blockade
por: Norwood, Timothy G., et al.
Publicado: (2017)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients: Ready for Prime Time?
por: Aras, Mandar A., et al.
Publicado: (2020)

Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity
por: Farina, Antonio, et al.
Publicado: (2023)

COVID-19 vaccine post-marketing surveillance: Cardiovascular doctors have a role to play!
por: Fournier, Dorine, et al.
Publicado: (2021)

Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database
por: Hu, Fangyuan, et al.
Publicado: (2021)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy–induced toxicities
por: Spetz, Johan K. E., et al.
Publicado: (2022)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

How we treat neurological toxicity from immune checkpoint inhibitors
por: Spain, Lavinia, et al.
Publicado: (2019)

Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Xia, Shuang, et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study
por: Diaz, Laurine, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors’ Effects on Calcified Aortic Plaques in Melanoma Survivors: A Retrospective Cohort Study
por: Turker, Isik, et al.
Publicado: (2023)

Therapeutic potential of DNA methyltransferase inhibitors with immune checkpoint inhibitor therapy in breast cancer
por: Luo, Na, et al.
Publicado: (2018)

Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study
por: Hu, Yizhang, et al.
Publicado: (2022)

Hepatotoxicity in immune checkpoint inhibitors: A pharmacovigilance study from 2014–2021
por: Xu, Ze, et al.
Publicado: (2023)

Retraction and republication: cardiac toxicity of hydroxychloroquine in COVID-19
por: Funck-Brentano, Christian, et al.
Publicado: (2020)

A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators
por: Garashi, Hamza Y., et al.
Publicado: (2022)

Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors
por: Picca, Alberto, et al.
Publicado: (2021)

Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
por: Joseph, Gwenyth J., et al.
Publicado: (2023)

Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Zhai, Yinghong, et al.
Publicado: (2022)

Pharmacovigilance
por: Griffin, J. P.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_q2bbie8j1jd4m9m61sbh82l862